Homepage Top Section1

The partnership will assess the safety, tolerability, and preliminary efficacy of UbiVac’s investigational product DRibble Platform Vaccine 001(DPV-001) in combination with BMS’ anti-OX40 (BMS-986178) combined with sequenced administration

According to IGY Life Sciences, the partnership with the clinical data and regulatory expert will focus on the nasal spray application of IgY-110, which it expects to be

The approval of Sarclisa and pom-dex combination is for people who had at least two prior therapies including lenalidomide and a proteasome inhibitor and have shown disease progression

The regulator has approved the company’s heart disease drug Brilinta based on positive data from the phase III THEMIS study. According to the company, the study demonstrated a

According to Rallybio, new investors who took part in the funding round included Viking Global Investors, TPG’s The Rise Fund, funds managed by Tekla Capital Management, F-Prime Capital,

The FDA approval allows Qinlock, a kinase inhibitor, to treat adult patients with advanced GIST who have secured prior treatment with three or more kinase inhibitors, including imatinib.

The approval has been granted for Tabrecta, a MET inhibitor, to treat adult patients with NSCLC whose tumours have a mutation, which leads to METex14 as detected by

VIR-2703 is a result of the recently announced expansion of the firms’ multi-target existing collaboration for the development and commercialisation of RNAi therapeutics for infectious diseases. The partnership

The open-label and phase 3 SIMPLE trial has assessed five-day and 10-day dosing durations of the investigational antiviral remdesivir in hospitalised patients with severe manifestations of COVID-19 disease.